PEPGEN INC. Operating Lease Right-of-Use Assets
PEPGEN INC. (PEPG) had Operating Lease Right-of-Use Assets of $17.91 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Operating Lease, Right-of-Use Asset $17.91M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $18.52M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $19.12M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $19.71M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $17.91M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $18.52M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $19.12M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $19.71M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $20.29M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $20.87M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $21.43M 10-K · filed 2026-03-04 |
| 2024-09-30 | $21.99M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $22.54M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $23.08M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $23.62M 10-K · filed 2025-02-24 |
| 2023-09-30 | $24.15M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $24.75M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $25.76M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $26.55M 10-K/A · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |